File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical Utility of Natriuretic Peptides in Dialysis Patients

TitleClinical Utility of Natriuretic Peptides in Dialysis Patients
Authors
Issue Date2012
Citation
Seminars in Dialysis, 2012, v. 25, n. 3, p. 326-333 How to Cite?
AbstractDialysis patients suffer a greatly heightened risk of cardiovascular morbidity and mortality. These patients also experience an extremely high prevalence of left ventricular hypertrophy, heart failure, and coronary artery disease. Thus, there is a clinical need to identify circulating biomarkers that have diagnostic value for cardiovascular disease and have prognostic importance so to facilitate earlier and more aggressive intervention. The natriuretic peptides, namely brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP), belong to a family of vasopeptide hormones that are released from the heart and play a major role in blood pressure regulation and volume homeostasis through their direct effects on the kidney and systemic vasculature and represent a favorable aspect of neurohumoral activation. Testing for BNP or NT-pro-BNP has recently emerged as important diagnostic tool for heart failure and a useful biomarker for risk stratification in the general population. In dialysis patients, there has been interest in evaluating the potential of BNP and NT-pro-BNP as markers of volume status as they are frequently elevated in dialysis patients. However, the interpretation of their levels is confounded by impaired renal clearance and preexisting LV abnormalities which have limited their applicability as a surrogate marker of volume status. In this article, we discuss the pathophysiology accounting for the elevation of natriuretic peptides in dialysis patients and review current evidence that supports their clinical utility as a diagnostic and prognostic tool in this population. © 2012 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/228467
ISSN
2015 Impact Factor: 1.912
2015 SCImago Journal Rankings: 0.739

 

DC FieldValueLanguage
dc.contributor.authorWang, Angela Yee Moon-
dc.date.accessioned2016-08-13T08:02:29Z-
dc.date.available2016-08-13T08:02:29Z-
dc.date.issued2012-
dc.identifier.citationSeminars in Dialysis, 2012, v. 25, n. 3, p. 326-333-
dc.identifier.issn0894-0959-
dc.identifier.urihttp://hdl.handle.net/10722/228467-
dc.description.abstractDialysis patients suffer a greatly heightened risk of cardiovascular morbidity and mortality. These patients also experience an extremely high prevalence of left ventricular hypertrophy, heart failure, and coronary artery disease. Thus, there is a clinical need to identify circulating biomarkers that have diagnostic value for cardiovascular disease and have prognostic importance so to facilitate earlier and more aggressive intervention. The natriuretic peptides, namely brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP), belong to a family of vasopeptide hormones that are released from the heart and play a major role in blood pressure regulation and volume homeostasis through their direct effects on the kidney and systemic vasculature and represent a favorable aspect of neurohumoral activation. Testing for BNP or NT-pro-BNP has recently emerged as important diagnostic tool for heart failure and a useful biomarker for risk stratification in the general population. In dialysis patients, there has been interest in evaluating the potential of BNP and NT-pro-BNP as markers of volume status as they are frequently elevated in dialysis patients. However, the interpretation of their levels is confounded by impaired renal clearance and preexisting LV abnormalities which have limited their applicability as a surrogate marker of volume status. In this article, we discuss the pathophysiology accounting for the elevation of natriuretic peptides in dialysis patients and review current evidence that supports their clinical utility as a diagnostic and prognostic tool in this population. © 2012 Wiley Periodicals, Inc.-
dc.languageeng-
dc.relation.ispartofSeminars in Dialysis-
dc.titleClinical Utility of Natriuretic Peptides in Dialysis Patients-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1525-139X.2012.01079.x-
dc.identifier.pmid22607214-
dc.identifier.scopuseid_2-s2.0-84862073759-
dc.identifier.volume25-
dc.identifier.issue3-
dc.identifier.spage326-
dc.identifier.epage333-
dc.identifier.eissn1525-139X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats